BR112022000413A2 - Formulação de longa duração contendo rivastigmina e método para preparar a mesma - Google Patents

Formulação de longa duração contendo rivastigmina e método para preparar a mesma

Info

Publication number
BR112022000413A2
BR112022000413A2 BR112022000413A BR112022000413A BR112022000413A2 BR 112022000413 A2 BR112022000413 A2 BR 112022000413A2 BR 112022000413 A BR112022000413 A BR 112022000413A BR 112022000413 A BR112022000413 A BR 112022000413A BR 112022000413 A2 BR112022000413 A2 BR 112022000413A2
Authority
BR
Brazil
Prior art keywords
long
preparing
rivastigmine
same
lasting
Prior art date
Application number
BR112022000413A
Other languages
English (en)
Inventor
Donghyun Park
Eunyoung Seol
Heekyoung Choe
Heeyong Lee
Juhan Lee
Yeonkyeong Lee
Original Assignee
G2Gbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2Gbio Inc filed Critical G2Gbio Inc
Publication of BR112022000413A2 publication Critical patent/BR112022000413A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

formulação de longa duração contendo rivastigmina e método para preparar a mesma. a presente invenção se refere a uma microesfera de liberação sustentada para formulações injetáveis de longa duração compreendendo um ou mais ingredientes ativos selecionados a partir do grupo que consiste de rivastigmina e sais farmaceuticamente aceitáveis da mesma fracamente solúveis e um polímero biodegradável, e uma formulação injetável de longa duração para prevenir ou tratar a doença de alzheimer compreendendo a mesma e um método para preparar a microesfera, e ela pode reduzir os efeitos colaterais do trato gastrointestinal do paciente, que são frequentemente vistos em agentes de administração oral convencionais, e aumentar a adaptabilidade de tomar o medicamento, maximizando assim o efeito terapêutico, ao prover uma formulação injetável de longa duração que compreende uma microesfera de liberação sustentada de rivastigmina, que tem um alto teor enquanto controla efetivamente a liberação inicial rápida do fármaco.
BR112022000413A 2019-07-12 2020-07-13 Formulação de longa duração contendo rivastigmina e método para preparar a mesma BR112022000413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190084775 2019-07-12
PCT/KR2020/009221 WO2021010719A1 (ko) 2019-07-12 2020-07-13 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법

Publications (1)

Publication Number Publication Date
BR112022000413A2 true BR112022000413A2 (pt) 2022-03-03

Family

ID=74211043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000413A BR112022000413A2 (pt) 2019-07-12 2020-07-13 Formulação de longa duração contendo rivastigmina e método para preparar a mesma

Country Status (11)

Country Link
US (1) US20220257518A1 (pt)
EP (1) EP3998065A4 (pt)
JP (2) JP7437074B2 (pt)
KR (4) KR20210007924A (pt)
CN (1) CN114126592A (pt)
AU (1) AU2020312361A1 (pt)
BR (1) BR112022000413A2 (pt)
CA (1) CA3143471C (pt)
MX (1) MX2022000489A (pt)
WO (1) WO2021010719A1 (pt)
ZA (1) ZA202201465B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210158232A (ko) * 2020-06-23 2021-12-30 주식회사 아울바이오 치매치료를 위한 장기지속형 주사제
CN115124456A (zh) * 2021-03-26 2022-09-30 上海博志研新药物技术有限公司 哌马色林药用盐、制备方法、含其的药物组合物及应用
CN113877000B (zh) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 注射用微球组合物及其应用
KR20240000406A (ko) * 2022-06-23 2024-01-02 주식회사 지투지바이오 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법
KR20240000405A (ko) * 2022-06-23 2024-01-02 주식회사 지투지바이오 약물과 파모산을 함유하는 서방성 미립구

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
EA016176B1 (ru) * 2006-12-18 2012-02-28 Такеда Фармасьютикал Компани Лимитед Композиция с замедленным высвобождением и способ её получения
CN101708164A (zh) * 2009-12-18 2010-05-19 苏州大学 一种卡巴拉汀缓释微球及其制备方法
KR20120011344A (ko) 2010-07-21 2012-02-08 에스케이케미칼주식회사 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구
KR101424163B1 (ko) 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
KR101307729B1 (ko) * 2012-11-19 2013-09-11 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자를 포함하는 주사용 조성물 및 이의 제조방법
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
KR101961848B1 (ko) * 2016-08-25 2019-03-25 영진약품 주식회사 C18:1, c18:1(oh) 또는 c18:2의 장쇄 지방산이 포함된 오일류를 포함한 방출억제제를 적용한 서방출성 마이크로스피어 및 이의 제조방법
KR101900482B1 (ko) 2017-01-17 2018-09-19 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법

Also Published As

Publication number Publication date
JP7437074B2 (ja) 2024-02-22
MX2022000489A (es) 2022-02-03
KR20220112737A (ko) 2022-08-11
US20220257518A1 (en) 2022-08-18
KR20210065921A (ko) 2021-06-04
CA3143471A1 (en) 2021-01-21
JP2022541011A (ja) 2022-09-21
EP3998065A1 (en) 2022-05-18
KR20220044921A (ko) 2022-04-12
EP3998065A4 (en) 2023-07-12
CN114126592A (zh) 2022-03-01
AU2020312361A1 (en) 2022-03-03
WO2021010719A1 (ko) 2021-01-21
ZA202201465B (en) 2023-11-29
CA3143471C (en) 2023-10-31
JP2024010233A (ja) 2024-01-23
KR20210007924A (ko) 2021-01-20

Similar Documents

Publication Publication Date Title
BR112022000413A2 (pt) Formulação de longa duração contendo rivastigmina e método para preparar a mesma
US11045424B2 (en) Extended release pharmaceutical formulation
AU2011260608B2 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
US20220347104A1 (en) Extended release pharmaceutical formulation and methods of treatment
BRPI0213653B1 (pt) Formulação farmacêutica que contém o 3-(3- dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo
US10869838B2 (en) Extended release pharmaceutical formulation
US11471416B2 (en) Extended release pharmaceutical formulation and methods of treatment
JP2016510068A (ja) デフェラシロクスの経口製剤
KR102194174B1 (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
AU2017252410A1 (en) Oral pharmaceutical compositions of mesalazine
US20210052517A1 (en) Extended release pharmaceutical formulation
EP3139906B1 (en) A slow-release pharmaceutical formulation
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
JP7381597B2 (ja) 持続放出性の医薬製剤
CN107205942A (zh) 包含富马酸二甲酯的药物基质制剂
JP6812104B2 (ja) 経口固形組成物
JP2016098230A (ja) 末梢血管疾患を有する患者における間欠跛行の症状を軽減するために用いられるキノリノン誘導体シロスタゾールの新規製剤
JP2016098230A5 (pt)
KR20230074522A (ko) 서방형 약학적 제형
EP3398587A1 (en) Compacted pharmaceutical preparation
WO2014060857A1 (en) Pharmaceutical compositions of diclofenac or salts thereof